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Aims: We investigated the effects of ketogenic diet (KD) on levels of tumor necrosis factor alpha (TNF-α, a
classical pro-inﬂammatory cytokine), BDNF (brain-derived neurotrophic factor, commonly associated with
synaptic plasticity), and S100B, an astrocyte neurotrophic cytokine involved in metabolism regulation.
Main methods: YoungWistar rats were fed during 8 weekswith control diet or two KD, containing different pro-
portions of omega 6 and omega 3 polyunsaturated fatty acids. Contents of TNF-α, BDNF and S100B were mea-
sured by ELISA in two brain regions (hippocampus and striatum) aswell as blood serum and cerebrospinal ﬂuid.
Key ﬁndings: Our data suggest that KD was able to reduce the levels of BDNF in the striatum (but not in hip-
pocampus) and S100B in the cerebrospinal ﬂuid of rats. These alterations were not affected by the proportion
of polyunsaturated fatty acids offered. No changes in S100B content were observed in serum or analyzed
brain regions. Basal TNF-α content was not affected by KD.
Signiﬁcance: These ﬁndings reinforce the importance of this diet as an inductor of alterations in the brain, and
such changes might contribute to the understanding of the effects (and side effects) of KD in brain disorders.© 2013 Elsevier Inc. Open access under the Elsevier OA license.Introduction
The ketogenic diets (KD) are diets that are high in fat, and have low
levels or no carbohydrate and low or normal levels of protein (Freeman
et al., 2007; Hartmanet al, 2007). This diet induces an increase in ketone
bodies that are available to the central nervous system (CNS) (Baranano
andHartman, 2008). Ketone bodies, mainly beta-hydroxy-butyrate, can
cross the blood brain barrier (BBB) through transporters of monocar-
boxylic acids (MCT), mainly via MCT1, present in the endothelial cells
of the BBB. In the CNS, ketone bodies are taken up and catabolized by
both neurons and astrocytes via MCT2 and MCT4, respectively (Pierre
and Pellerin, 2005; Hartman et al., 2007)
It has been proposed that ketone bodies partially replace glucose con-
sumption as a fuel tomaintain neuronal activity (Melo et al., 2006), but it
is not clear whether these compounds are directly involved in the bene-
ﬁcial effects of this diet on the CNS. In addition to ketone bodies, the con-
tent and proportion of polyunsaturated fatty acids have been suggested
to be mediators of the effects of KD on brain disorders (Cunnane, 2004;
Borges, 2008).
KD were originally proposed for epileptic disorders (Baranano and
Hartman, 2008)and have a wide use today for treating brain disorders
including Parkinson's disease (Vanitallie et al., 2005), Alzheimer's dis-
ease (Van der Auwera et al., 2005; Henderson, 2008), amyotrophicS, Ramiro Barcelos, 2600-anexo,
5.
ier OA license.lateral sclerosis, depression (Zhao et al., 2006) brain ischemia (Tai
and Truong, 2007), bipolar disease (El-Mallakh and Paskitti, 2001)
and autism (Evangeliou et al., 2003).
The neuroprotectivemechanisms that are induced by the KD are un-
known. However, some current hypotheses suggest that changes in the
mitochondrial and antioxidant activities (Maalouf et al., 2009) are in-
volved in antiepileptic activity. In support of this, KD fed rats exhibit in-
creased UCP expression and activity (Sullivan et al., 2004), as well as
increased glutathione content (Jarrett et al., 2008) and glutathione per-
oxidase activity (Ziegler et al., 2003) in the hippocampus.
It is important tomention thatmitochondrial and antioxidant changes
are also observed under caloric restriction, which has a neuroprotective
effect on several brain diseases (Maalouf et al., 2009).
The activity of the ketogenic diet and caloric restriction has been
attributed to changes in the balance and expression of inﬂammatory
(e.g. cytokines) and neurotrophic (e.g. neurotrophins) factors. In sup-
port this hypothesis, the ability of 2-deoxy-glucose (a glucose analog
able to induce a ketogenic state) to act as a neuroprotective agent in a
transgenic mouse model of Alzheimer's disease has been previously
studied (Yao et al., 2011). These authors found, in parallel with
changes in bioenergetic capacity, an increase in the expression of
brain-derived neurotrophic factor (BDNF) and nerve growth factor
(NGF). With regard to KD feeding, some reports suggest changes in
inﬂammatory parameters (Adibhatla and Hatcher, 2008; Ruskin et
al., 2009; Jeong et al., 2011). A decrease in tumor necrosis factor
alpha (TNF-α) was observed in the hippocampus of KD treated rats,
as well as in HT22 cells exposed to acetoacetate (Jeong et al., 2011).
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classical pro-inﬂammatory cytokine) and BDNF (an important neuro-
trophin associated with synaptic plasticity), as well as S100B, an astro-
cyte protein involved in metabolism regulation, which is secreted in
inﬂammatory conditions (de Souza et al., 2009; Guerra et al., 2011)
and has a trophic extracellular role (Goncalves et al., 2008; Donato et
al., 2009). Our working hypothesis was that KD induces an increase in
the BDNF/TNF-alpha ratio, where an increase in numerator (BDNF)
and/or a decrease in the denominator (TNF-α) could be, simply, inter-
preted as favorable signal for cell survival in brain tissue. Wistar rats
were fed during 8 weeks with control diet or two KD, containing differ-
ent proportions ofω-6 andω-3 polyunsaturated fatty acids (PUFA), and
two brain regions, hippocampus and striatumwere analyzed, as well as
blood serum and cerebrospinal ﬂuid.Materials and methods
Animals and diet
MaleWistar rats (30 days old)were obtained fromour breeding col-
ony (in the Department of Biochemistry, UFRGS) andmaintained under
controlled light and environmental conditions (12 h light/12 h dark
cycle at a constant temperature of 22 ± 1 °C). Animals were divided
into three groups of twenty animals with the respective diets: control
(C), standard ketogenic diet (s-KD) and enriched omega-3 ketogenic
diet (ω3-KD). KD was formulated based on a previous study (Ziegler
et al., 2002), but using soy protein instead of casein as in the standard
ration for rats and mice from Nuvital, Nuvilab CR-1 (Curitiba, Brazil).
Chow composition is detailed in Table 1. All animals were fed ad libitum
and had free access to water for 8 weeks. Procedures were in accor-
dance with the National Institute of Health Guide for the Care and Use
of Laboratory Animals (NIH Publications No. 80-23) following the regu-
lations of the local animal house authorities.
During treatment, the rats were weighed weekly and observed for
behavior and coat to check if the diet was contributing to malnutri-
tion and protein loss.Table 1
Composition of the control, standard ketogenic (s-KD) and ketogenic with increase
omega-3 (w3-KD) diets.
Control
(g/100 g)
s-KD
(g/100 g)
w3-KD
(g/100 g)
Asha 4 4 4
Vitaminb 1 1 1
Fiber 1 1 1
Proteinc 33.5 33.5 33.5
DL-methionined 0.3 0.3 0.3
Carbohydrates 55.2 – –
Soybeanoil 0.5 0.5 0.5
Fishoile – – 1.0
Lard 4.5 59.7 58.7
Rate w6/w3 11:1 10:1 5:1
a Mineral salt mixture (from Roche, São Paulo, Brazil), mg/100 g of diet: NaCl, 557;
KI, 3.2; KH2PO4, 1556; MgSO4, 229; CaCO3, 1526; FeSO4·7H2O, 108; MnSO4·H2O, 16;
ZnSO4·7H2O, 2.2; CuSO4·5H2O, 1.9; CoCl2·6H2O, 0.09.
b Vitamin mixture: mg/100 g of diet (from Roche, São Paulo, Brazil): Vitamin A
(retinyl acetate), 4; Vitamin D (cholecalciferol), 0.5; Vitamin E (DL-α-tocopheryl ace-
tate), 10; menadione, 0.5; choline, 200; PABA 10; inositol 10; niacin (nicotinic acid),
4; pantothenic acid (calcium D-pantothenate), 4; riboﬂavin, 0.8; thiamin (thiamine hy-
drochloride), 0.5; pyridoxine (pyridoxine hydrochloride), 0.5; folic acid, 0.2; biotin
[D-(+)-biotin], 0.04; Vitamin B12, 0.003.
c Soy protein isolate, purity 97% (from Solae, Esteio, Brazil).
d D-L-methionine (from Merk, Rio de Janeiro, Brazil).
e Fish oil: docosahexaenoic acid (DHA) 5:1 eicosapentaenoic acid (EPA) (Naturalis
SA, Brazil.).Analysis of serum
Rats were anesthetized by intraperitonial injection of ketamine
(75 mg/kg) and xylasine (10 mg/kg) and blood was collected by cardi-
ac puncture; serumwas obtained by centrifuging at 1000 ×g for 10 min
(Eppendorf 5402, Hamburg, Germany) before storing for 24 h at 8 °C
until the biochemical measurement of glucose, β-hydroxybutyrate,
cholesterol, triacylglycerol, HDL cholesterol, urea, uric acid, albumin
and total protein.
Biochemical analyses were carried out with colorimetric kits by
Human Brazil, using speciﬁc tests: glucose (GPO-PAP method, Ref
10261) total protein (biuret method, Ref 013), albumin (bromocresol
method, Ref 001), urea (enzymatic colorimetric test, Ref 10505), uric
acid (enzymatic colorimetric test, Ref 10687), triglycerides (triglycer-
ides liquicolor test, Ref 10726), cholesterol (enzymatic colorimetric
test, Ref 10013) and HDL cholesterol (cholesterol precipitation and en-
zymatic colorimetric, Ref 004). Serum β-hydroxybutyrate was deter-
mined using the enzymatic colorimetric test by Ranbut (Ref RB1007).
Brain tissue, CSF and serum samples
For ventricular access, the anesthetized rats were placed in a ste-
reotaxic apparatus, then, the cerebrospinal ﬂuid CSF was obtained
by puncture of the cisterna magna using an insulin syringe. A maxi-
mum volume of 30 μL was collected over a 3-min period to minimize
risk of brain stem damage. Cerebrospinal ﬂuid samples were frozen
(−70 °C) until used for determination of immunocontent of S100B
and TNF-α. Blood samples were obtained as described above and
also frozen for S100B and TNF-α measurements. The rats were killed
by decapitation and the brains were removed and placed in cold sa-
line medium with following composition (in Mm): 120NaCl; 2KCl;
1CaCl2; 1MgSO4; 25 HEPES; 1KH2PO4 and 10 Glucose, adjusted to
pH 7.4 and previously aerated with O2. Hippocampi and striatum
were dissected on ice and transverse slices of 0.3 mm were obtained
using a McIlwain Tissue Chopper.
Quantiﬁcation of S100B
Slices were homogenized in PBS (50 mM NaCl, 18 mM Na2HPO4,
83 mM NaH2PO4·H2O, pH 7.4), containing 1 mM EGTA and 1 mM
phenylmethyl-sulphonyl ﬂuoride (PMSF). The S100B content in the
CSF, serum and brain tissue was measured by ELISA, as described
previously (Leite et al., 2008). Brieﬂy, 50 μl of sample plus 50 μl of Tris
buffer were incubated for 2 h on a microtiter plate that was previously
coated with monoclonal anti-S100B. Polyclonal anti-S100 was incubat-
ed for 30 min and then peroxidase-conjugated anti-rabbit antibodywas
added for a further 30 min. The color reaction with OPD was measured
at 492 nm. The standard S100B curve ranged from 0.02 to10 ng/ml.
Quantiﬁcation of TNF-alpha
Hippocampal and striatal soluble extracts were prepared by a lysis
buffer followed by centrifugation at 1000 ×g for 5 min at 4 °C. This
assay was carried out in 100 μL of supernatant, using a rat TNF-α
ELISA (eBioscience, Ref. 88-7340, San Diego, USA).
Quantiﬁcation of BDNF
For BDNF measurement slices were homogenized in lysis buffer:
100 mM Tris/HCl, pH 7.0, 2% bovine serum albumin (BSA), 1 M NaCl,
4 mM EDTA.Na2, 2% Triton X-100, 0. 1% sodium azide and protease in-
hibitors (fromSigma) containing 5 μg/mL aprotinin, 0.5 μg/mL antipain,
17 μg/mLbenzamidine, 0.1 μg/mLpepstatin A and 17 μg/mL PMSF. Hip-
pocampal and striatal homogenates were centrifuged at 14 000 ×g for
30 min at 4 °C and soluble samples were used for BDNF ELISA
(Millipore, Ref. CYT306, Billerica, USA).
Table 2
Serum biochemistry of rats fed control and different kinds of ketogenic diets for
8 weeksa.
Control s-KD w3-KD
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Protein was measured by Lowry's method, modiﬁed by Peterson,
using bovine serum albumin as a standard (Peterson, 1977).(mg/dL)
Protein 1.76 ± 0.17 1.76 ± 0.18 1.74 ± 0.20
HDL 1.08 ± 0.06 0.93 ± 0.03 0.74 ± 0.07
(g/dL)
Albumin 2.44 ± 0.06 2.47 ± 0.06 2.51 ± 0.08
(mmol/L)
Glucose 7.0 ± 066 7.89 ± 0.40 8.18 ± 0.59
Triglycerides 0.24 ± 0.04 0.27 ± 0.04 0.26 ± 0.03
Cholesterol 1.28 ± 0.05 1.14 ± 0.04 1.08 ± 0.10
β-Hydroxybutyrate 0.14 ± 0.01 0.25 ± 0.04⁎ 0.29 ± 0.04⁎
Urea 4.84 ± 0.18 3.94 ± 0.29 ⁎ 4.08 ± 0.23Statistical analysis
Data from the experiments are presented as mean ± standard
error mean and analyzed statistically by two-way analysis of variance,
followed by the Tukeys' test. ANOVA of repeated measurements and
one-way analysis of variance were used to compare the growth of
rats during treatments. The level of statistical signiﬁcance was set at
P b 0.05. All analyses were performed using the Statistical Package
for the Social Sciences (SPSS) software.Uric acid 0.35 ± 0.04 0.34 ± 0.04 0.28 ± 0.02
a Values are means ± S.E.M, n = 10.
⁎ Statistically signiﬁcant from control by one-way ANOVA (P b 0.05).Results
Body weight and biochemical serum parameters
Young rats were fed on ketogenic diets or the control diet for
8 weeks. During the ﬁrst two weeks they gained weigh at the same
rate. However, from the second week on, rats fed on the ketogenic
diet had a lower weight gain (F2,207 = 101.993, P b 0.001) (Fig. 1),
independently of whether the diet was enriched in ω-3 fat acids or
not (F16,207 = 2.318, P = 0.004). No signiﬁcant change was observed
between the groups for the total serum protein and albumin content
at the end of treatment (Table 2). Lipidemia (based on total cholester-
ol and triglycerides) and glycemia were also not different between
the groups. The increase in ketonemia (evaluated by measuring
serum β-hybroxybutyrate) was conﬁrmed in both ketogenic groups
(F2,26 = 6.172, P = 0.006). We found a small decrease in serum
urea in ketogenic rats (about 20%) that was signiﬁcant only in rats
fed on a standard ketogenic diet (F2,23 = 4.032, P = 0.032).Hippocampal, striatal, CSF and serum contents of TNFα
The immunocontent of TNFα, a pro-inﬂammatory cytokine, did not
change after ketogenic diet in the two brain regions studied: hippocam-
pus (F2,43 = 0.720, P = 0.720) and striatum (F2,43 = 1.130, P = 0.332)
(Fig. 2), as well as in the cerebrospinal ﬂuid (F2,6 = 0.398, P = 0.688)
and blood serum (F2,38 = 0.599, P = 0.554) (data not shown).Fig. 1. Evolution of body weight in rats fed control chow (circle), standard ketogenic
diet (s-KD) (square) or enriched omega-3 ketogenic diet (ω3-KD) (triangle symbol)
for 8 weeks. Values are mean ± S.E.M. of 17–19 rats. All groups gained body weight
during the different diets (repeated measures ANOVA). *Signiﬁcantly different rate of
growth between control and KD rats from the second week onwards (one-way
ANOVA followed by Tukey's Test, P b 0.001).Hippocampal and striatal contents of BDNF
The hippocampal content of BDNF, an important neurotrophin,
was similar among the groups (F2,20 = 0.143, P = 0.868) (Fig. 3).
However, the striatal content was signiﬁcantly lower in ketogenic
rats, independently of whether the diet was enriched in ω-3 fat
acids or not (F2,12 = 4.584, P = 0.033).Hippocampal and striatal contents of S100B
No changes in the content of S100B, an astroglial protein marker,
were observed in the hippocampus or striatum, when comparing
them with their respective controls (Fig. 4). The content of striatal
S100B was different for rats fed on the standard ketogenic diet and
enriched in ω-3 ketogenic diet (F2,41 = 4.179, P = 0.022).Cerebrospinal ﬂuid and serum contents of S100B
No signiﬁcant changes were observed in serum S100B among the
groups (F2,43 = 1.984, P = 0.150) (Fig. 5A).The immunocontent of
S100B in the cerebrospinal ﬂuid was signiﬁcantly lower in ketogenic
rats, whether fed on the standard or ω-3 enriched ketogenic diet
(Fig. 5B) (F2,20 = 3.830, P = 0.039).Fig. 2. Immunocontent of TNF-alpha in hippocampus and striatum. Rats were fed with
control, standard ketogenic (s-KD) and ketogenic with increased omega-3 (w3-KD)
diets for 8 weeks. TNF-α was measured by ELISA. Values are mean ± S.E.M. of 10
rats (one-way ANOVA, P b 0.05).
Fig. 3. Immunocontent of BDNF in the hippocampus and striatum. Rats were fed with
control, standard ketogenic (s-KD) and ketogenic with increased omega-3 (w3-KD)
diets for 8 weeks. BDNF was measured by ELISA. Values are mean ± S.E.M. of 10
rats.⁎ Signiﬁcantly different from control group of BDNF in the striatum (one-way
ANOVA followed by Tukey's Test, P b 0.05).
Fig. 5. S100B levels of serum (A) and cerebrospinal ﬂuid (B) of rats treated with con-
trol, standard ketogenic (s-KD) and ketogenic with increase omega-3 (ω3-KD) diets.
Values are mean ± S.E.M. of 10 rats.⁎ Signiﬁcantly different from control group of
S100B in CSF (one-way ANOVA followed by Tukey's Test, P b 0.05).
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KD have been proposed as a neuroprotective approach for several
brain disorders, particularly epilepsies, but also in neurodegenerative
diseases such as Parkinson's disease, Alzheimer's disease, amyotrophic
lateral sclerosis and psychiatric disorders such as depression and bipo-
lar disease (El-Mallakh and Paskitti, 2001; Evangeliou et al., 2003; Van
der Auwera et al., 2005; Vanitallie et al., 2005; Zhao et al., 2006; Tai
and Truong, 2007; Henderson, 2008). We focused this study on two
brain regions, the hippocampus and striatum, because these are com-
monly associated with the brain disorders mentioned. However, other
brain regions could be investigated in further studies.
Knowledge regarding the effects of KD on brain is limited and
neuroprotective mechanisms remain elusive. The production KB per
se does not explain all the changes observed (Freeman et al., 2007;
Hartman et al., 2007) and some studies have suggested that the avail-
ability of polyunsaturated fatty acids, derived from the KD, may un-
derlie, in part, such changes (Cunnane, 2004; Borges, 2008). The
changes induced by KD could affect brain levels of neurotrophins
and cytokines. In order to investigate this hypothesis we measured
the brain contents of BDNF, TNF-alpha and S100B, in rats treated
with two different KD that contained different proportions of ω3
and ω6 fatty acids.Fig. 4. Immunocontent of S100B in hippocampus and striatum. Rats were fed with con-
trol, standard ketogenic (s-KD) and ketogenic with increased omega-3 (w3-KD) diets
for 8 weeks. S100B was measured by ELISA. Values are mean ± S.E.M. of 10 rats. The
levels of S100B in hippocampus were the same for the different treatments (One-way
ANOVA, P b 0.05). *Signiﬁcant difference in the levels of S100B in the striatum of rats
treated with different KD (one-way ANOVA followed by Tukey's Test P b 0.05).It is important tomention that our KD treatment reproduced changes
previously observed in weight body development (Ziegler et al., 2002).
In fact, KD induced a lower body weight gain from the second week on-
wards and this change did not differ between the two types of KD. No
signiﬁcant changes were observed in biochemical serum parameters
such as lipidemia, glycemia and proteinemia after 8 weeks of KD. In
agreementwith previous studies,we did notﬁnd changes in lipoproteins
and triacylglycerol (Ziegler et al., 2002; Ribeiro et al., 2008), but long-
term KD appears to improve other risk factors for heart disease (e.g. in-
creases high-density lipoprotein and decreases triacylglycerol) in obese
patients (Dashti et al., 2003). Glycemia clearly decreases in the ﬁrst
2 weeks of KD in rats (Leino et al., 2001; Nylen et al., 2005); a small de-
crease in glycemia has been described after 4 weeks of KD (Bielohuby et
al., 2011); and no signiﬁcant change in glycemia has been described after
8 weeks (Kinzig et al., 2010). On the other hand, the increment in
ketonemia, as we observed, is evidently independent of the duration of
KD.
A recent study showed the effect of fat/protein ratio on the genera-
tion of ketosis in KD (Bielohuby et al., 2011). Authors observed that a
higher fat/protein ratio (e.g. 7.5/1) caused a higher ketosis and that a
lower ratio (e.g. 5.5/3) did not cause ketosis. Our KD (that has an appar-
ent fat/protein of 6/3.3)was able to cause a signiﬁcant increase of serum
beta-hydroxybutirate. It is important to consider the net protein utiliza-
tion of soy protein (about 0.66 if compared with casein) (Erdman and
Fordyce, 1989) used in this study; therefore the fat/protein ratio was
about 6/2.2. Moreover, the neuroprotective effect of KD (at least against
PTZ-induced seizure) was not correlated with ketone body levels and
could be affected by fat source (e.g. lard or seed oils) (Likhodii et al.,
2000). Herein, we found no difference on ketonemia when induced by
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serum urea was observed in standard KD treated rats conﬁrming previ-
ous results (Ziegler et al., 2002), but this decrease was not signiﬁcant in
ω3-KD rats.
BDNF iswidely expressed in the rodent brain, and is especially abun-
dant in the hippocampus, cerebral cortex, cerebellum, striatum and the
amygdala (Kawamoto et al., 1996), where it modulates synaptic trans-
mission, plasticity and survival of different types of neurons (Noble et
al., 2011). Our study conﬁrmed that BDNF immunocontent in the hippo-
campus is higher than in the striatum in Wistar rats. No changes in
BDNF content were induced by KD in the hippocampus, but unexpect-
edly a decrease in BDNF was observed in the striatum. Several studies
have suggested that peripheral metabolic changes could alter the ex-
pression and release of brain BDNF. For example, physical exercise in-
duced an upregulation of the BDNF in the hippocampus and might
therefore play an important role in the enhancement of cognitive func-
tions in rodent models and in mood in humans (Zoladz and Pilc, 2010).
Caloric restriction also increases BDNF levels in brain structures, such as
the hippocampus, cerebral cortex, and striatum of rats (Duan et al.,
2001). All these studies have suggested a neuroprotective role of
BDNF, including in dopaminergic neurons (Peng et al., 2011). Therefore,
current data suggest that KD may not be beneﬁcial for striatum cells.
The apparently harmful effect of KD in speciﬁc brain regions has
been also reported. For example, oxidative stress is reduced by KD
in the hippocampus, but is exacerbated in the cerebellum (Ziegler et
al., 2003); morphological changes induced by KD were apparently
beneﬁcial in the CA1 region of the hippocampus, but not in the den-
tate gyrus (Balietti et al., 2008). However, we investigated only the
basal effect of KD and further studies should focus on investigating
the effects of KD in the striatum and hippocampus under conditions
of injury, such as epilepsy or Parkinson's disease models.
It is important to mention that KD (at least when fat/protein ratio is
elevated)was able to increase blood free fatty acids in rats (Bielohuby et
al., 2011). It should be pointed out that KD in children also increases free
fatty acids content, particularly for PUFA (Fraser et al., 2003). Moreover,
a decrease in dietaryω-3 PUFA reduces rat brain BDNF (Rapoport et al.,
2007; Kim et al., 2011). Therefore, KD could increase brain BDNF. On the
other hand, it has been suggested that raising free fatty acid decreases
circulating BDNF in healthy humans (Karczewska-Kupczewska et al.,
2012). The relationship between free fatty acids and BDNF (central
and peripheral) deserves clariﬁcation in further KD studies. In this
study, standard or ω-3 enriched KD reduced the content of striatal
BDNF.
Moreover, we did not observe any changes in basal TNF-α content
in the hippocampus and striatum induced by KD. TNF-α is a pro-
inﬂammatory cytokine that is mainly upregulated and released by
glial cells in brain, particularly under conditions of injury (Wilson et
al., 2002; McCoy and Tansey, 2008; Nishioku et al., 2010) and chronic
elevations of this cytokine are observed in neurodegenerative dis-
eases (Stoll and Jander, 1999; Eskandari et al., 2003; McCoy and
Tansey, 2008; Krause and Muller, 2010). Cytokines work as bidirec-
tional signals of communication between CNS and the peripheral im-
mune system (Wilson et al., 2002). It has been demonstrated that
metabolic modiﬁcations alter the expression and release of cytokines.
For example, a high cholesterol diet enhances the expression of
pro-inﬂammatory cytokines in rats (Lewis et al., 2010) and caloric re-
striction in aging rodents models down regulate the expression of in-
ﬂammatory cytokines (Wilson et al., 2002). Moreover, KD reduced
the levels of the proinﬂammatory cytokines (IL-1β, IL-6, and TNF-α)
and promoted the survival of dopaminergic neurons in a mice
model of Parkinson's disease with MPTP (Yang and Cheng, 2010).
Therefore, in contrast to our hypothesis, we did not ﬁnd an increase
in basal BDNF/TNF-α ratio induced by KD and, in the striatum, we
even found a decrease in this ratio.
S100B is a calcium-binding proteinmainly expressed and secreted by
astrocyte cells in the central nervous system. In the cell, it can regulateglucose metabolism, the cytoskeleton and proliferation (Donato et al.,
2009). Extracellular S100B plays a trophic role in neuron and glial cell
cultures and acute elevation of this protein in cerebrospinal ﬂuid has
been observed in injury conditions (Goncalves et al., 2008). This protein
is secreted in vitro and in vivo in response to inﬂammatory signals, such
as interleukin 1β and LPS (de Souza et al., 2009; Guerra et al., 2011).
We did not ﬁnd any changes in S100B content in the hippocampus
and striatum induced by KD, when compared with control rats. How-
ever, a direct comparison between s-KD and ω3-KD suggests a differ-
ence in the expression of this protein. The functional meaning of this
ﬁnding is unclear, but is possible to conceive that PUFA modulate the
expression of S100B, particularly in the striatum. Arundic acid has
been shown to be able to inhibit the expression of S100B, but the
transcriptional mechanism involved is unknown (Asano et al., 2005).
On the other hand, the S100B content decreases in CSF after KD feed-
ing. We previously reported this effect (Ziegler et al., 2004) and sug-
gested that it could be mediated by elevated levels of KB, as reported
in astrocyte cultures (Leite et al., 2004). This could be triggered by
and/or be indicative of changes in fuelmetabolism, i.e. a decrease in glu-
cose utilization. In fact, in rats submitted to the intracerebroventricular
administration of streptozotocin (Rodrigues et al., 2009) or chronic ce-
rebral hypoperfusion (Vicente et al., 2009), two conditions associated
with the decrease in glucose consumption, a decrease in cerebrospinal
ﬂuid S100B has been reported. This decrease, alone, could be inter-
preted as an extracellular neurotrophic decrease and therefore, as a
“bad” signal. However, elevated levels of S100B in cultures are poten-
tially harmful because they induce cell death and, in some conditions,
extracellular S100B decrease could be conceived as a “good” signal.
Moreover, serum S100B did not change during the KD, reinforcing
the idea that changes in CSF S100B are not necessarily accompanied
by changes S100B serum. This ﬁnding is interesting, because adipose
tissue is an important source of serum S100B (Goncalves et al., 2010)
and adipose mass considerably increases during KD (Ribeiro et al.,
2008). Our present data suggest that adipose release of S100B was
not affected by KD. These apparent independent actions of the brain
and adipose tissue, based on S100B levels in CSF and serum, were
also observed during fasting (Netto et al., 2006) and LPS stimulation
(Guerra et al., 2011).
Conclusion
Our data suggest that KD for 8 weeks was able to reduce the levels
of two putative neurotrophic molecules: BDNF in the striatum and
S100B in the cerebrospinal ﬂuid of rats. These alterations were not af-
fected by the proportion of PUFA of the KD offered. Although the
meaning of these changes is debatable, at this moment, these ﬁndings
reinforce the importance of this diet as an inductor of alterations in
the brain, and might contribute to the understanding of the effects
(or side effects) of KD in brain disorders.
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